Drug-induced lupus erythematosus with emphasis on skin manifestations and the role of anti-TNFα agents;Medikamenteninduzierter Lupus erythematodes unter besonderer Berücksichtigung von Hautmanifestationen und Anti-TNFα-Therapeutika

JDDG - Journal of the German Society of Dermatology

Volumn 10, Issue 12, 2012, Pages 889-897

  Dalle Vedove, Camilla ^a   Simon, Jan C ^b   Girolomoni, Giampiero ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

drug reactions; drug induced lupus erythematosus; lupus erythematosus

Indexed keywords

ANTIINFECTIVE AGENT; ANTINUCLEAR ANTIBODY; FLUOROURACIL; HISTONE ANTIBODY; HYDRALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT; PANTOPRAZOLE; PROCAINAMIDE; PROTON PUMP INHIBITOR; QUINIDINE; TERBINAFINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTHRITIS; CHRONIC CUTANEOUS LUPUS ERYTHEMATOSUS; DISEASE ASSOCIATION; DRUG EXPOSURE; HUMAN; IDIOPATHIC DISEASE; INFLAMMATION; LUPUS LIKE SYNDROME; RARE DISEASE; REVIEW; SEROLOGY; SKIN LUPUS ERYTHEMATOSUS; SKIN MANIFESTATION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; DRUG ERUPTIONS; HUMANS; LUPUS ERYTHEMATOSUS, CUTANEOUS; PROTON PUMP INHIBITORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84870657449     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2012.08000.x     Document Type: Review

References (59)

1. Pons-Estel GJ, Alarcõn GS, Scofield L, Reinlib L, Cooper GS,. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum 2010; 39: 257-68.
2. Tsokos GC,. Systemic lupus erythematosus. N Engl J Med 2011; 365: 2110-21.
3. Chang C, Gershwin ME,. Drug-induced lupus erythematosus. Incidence, management and prevention. Drug Saf 2011; 34: 357-74.
4. Marzano AV, Vezzoli P, Crosti C,. Drug-induced lupus: an update on its dermatological aspects. Lupus 2009; 18: 935-40.
5. Antonov D, Kazandjieva J, Etugov D, Gospodinov D, Tsankov N,. Drug-induced lupus erythematosus. Clin Dermatol 2004; 22: 157-66.
6. Rubin RL,. Drug-induced lupus. Toxicology 2005; 209: 135-47.
7. Chang C, Gershwin ME,. Drugs and autoimmunity-a contemporary review and mechanistic approach. J Autoimmun 2010; 34: J266-75.
8. Peroni A, Colato C, Zanoni G, Girolomoni G,. Urticarial lesions: if not urticaria, what else? The differential diagnosis of urticaria: part II. Systemic diseases. J Am Acad Dermatol 2010; 62: 557-70.
9. Zirwas MJ, Kress DW, Deng JS,. The utility of antihistone antibody screening in the diagnosis of drug-induced lupus erythematosus. Arch Dermatol 2004; 140: 494-5.
10. Vasoo S,. Drug-induced lupus: an update. Lupus 2006; 15: 757-61.
11. Dalle Vedove C, Del Giglio M, Schena D, Girolomoni G,. Drug-induced lupus erythematosus. Arch Dermatol Res 2009; 301: 99-105.
12. Sturkenboom MC, Meier CR, Jick H, Stricker B,. Minocycline and lupus-like syndrome in acne patients. Arch Intern Med 1999; 159: 493-7.
13. Borchers AT, Keen CL, Gershwin ME,. Drug-induced lupus. Ann N Y Acad Sci 2007; 1108: 166-82.
14. Margolis DJ, Hoffstad O, Bilker W,. Association or lack association between tetracycline class antibiotics used for acne vulgaris and lupus erythematosus. Br J Dermatol 2007; 157: 540-6.
15. Borg FA, Isenberg DA,. Syndromes and complications of interferon therapy. Curr Opin Rheumatol 2007; 19: 61-6.
16. Sladkova V, Mares J, Lubenova B, Hlustik P, Kanovsky P,. Drug-induced systemic lupus erythematosus in interferon beta-1b therapy. Neuro Endocrinol Lett 2011; 32: 4-6.
17. Yokoyama T, Usui T, Kiyama K, Nakashima R, Yukawa N, Kawabata D, Nojima T, Ohmura K, Fujii T, Mimori T,. Two cases of late-onset drug-induced lupus erythematosus caused by ticlopidine in elderly men. Mod Rheumatol 2010; 20: 405-9.
18. Lowe G, Henderson CL, Grau RH, Hansen CB, Sontheimer RD,. A systematic review of drug-induced subacute cutaneous lupus erythematosus. Br J Dermatol 2011; 164: 465-72.
19. Marzano AV, Lazzari R, Polloni I, Crosti C, Fabbri P, Cugno M,. Drug-induced subacute cutaneous lupus erythematosus: evidence for differences from its idiopathic counterpart. Br J Dermatol 2011; 165: 335-41.
20. Hillesheim PB, Bahrami S, Brooke GJ, Jeffrey PC,. Tissue eosinophilia. Not an indicator of drug-induced subacute cutaneous lupus erythematosus. Arch Dermatol 2012; 148: 190-3.
21. Gubinelli E, Cocuroccia B, Girolomoni G,. Subacute cutaneous lupus erythematosus induced by nifedipine. J Cutan Med Surg 2003; 7: 243-6.
22. Lorentz K, Booken N, Goerdt S, Goebeler M,. Subacute cutaneous lupus erythematosus induced by terbinafine: case report and review of literature. J Dtsch Dermatol Ges 2008; 6: 823-7.
23. Dam C, Bygum A,. Subacute cutaneous lupus erythematosus induced or exacerbated by proton pump inhibitors. Acta Derm Venereol 2008; 88: 87-9.
24. Chen M, Crowson AN, Woofter M, Luca MB, Magro CM,. Docetaxel (taxotere) induced subacute cutaneous lupus erythematosus: report of 4 cases. J Rheumatol 2004; 31: 818-20.
25. Guhl G, Diaz-ley B, Garcia-Garcia C, Fraga J, Garcia-Diez A,. Chemotherapy-induced subacute lupus erythematosus. Lupus 2009; 18: 859-60.
26. Trancart M, Cavailhes A,. Balme B, Skowron F. Anastrozole-induced subacute cutaneous lupus erythematosus. Br J Dermatol 2008; 158: 628-9.
27. Correia O, Lomba Viana H, Azevedo R, Delgado L, Polonia J,. Possible phototoxicity with subsequent progression to discoid lupus following pantoprazole administration. Clin Exp Dermatol 2001; 26: 455-6.
28. Costa MF, Said NR, Zimmermann B,. Drug-induced lupus due to anti-tumor necrosis factor α agents. Semin Arth Rheum 2008; 37: 381-7.
29. Schmitt V, Meuth AM, Amler S, Kuehn E, Haust M, Messer G, Bekou V, Sauerland C, Metze D, Kopcke W, Bonsmann G, Kuhn A,. Lupus erythematosus tumidus is a separate subtype of cutaneous lupus erythematosus. Br J Dermatol 2009; 162: 64-73.
30. Bokle BC, Baltaci M, Weyrer W, Sepp NT,. Bortezomib-induced lupus erythematosus tumidus. Oncologist 2009; 14: 637-9.
31. Schneider SW, Staender S, Schluter B, Luger TA, Bonsmann G,. Infliximab-induced lupus erythematosus tumidus in a patient with rheumatoid arthritis. Arch Dermatol 2006; 142: 115-6.
32. Sohl S, Renner R, Winter U, Bodendorf M, Paasch U, Simon JC, Treudler R,. Drug-induced lupus erythematosus tumidus during treatment with adalimumab. Hautarzt 2009; 60: 826-9.
33. Schepis C, Lentini M, Siragusa M, Batolo D,. Ace-inhibitor-induced drug eruption resembling lymphocytic infiltration (of Jessner-Kanof) and lupus erythematosus tumidus. Dermatology 2004; 208: 354-55.
34. Williams EL, Gadola S, Edwards CJ,. Anti-TNF-induced lupus. Rheumatology (Oxford) 2009; 48: 716-20.
35. De Bant M, Sibilia J, Le Loet X, Prouzeau S, Fautrel B, Marcelli C, Boucquillard E, Siame JL, Mariette X,; Club Rhumatismes et Inflammation. Systemic lupus erythematosus induced by anti-tumor necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 2005; 7: R545-51.
36. Soforo E, Baumgartner M, Francis L, Allam F, Phillips PE, Perl A,. Induction of systemic lupus erythematosus with tumor necrosis factor blockers. J Rheumatol 2010; 37: 1.
37. Ramos-Casals M, Brito-Zeron P, Soto MJ, Cuadrado MJ, Khamashta MA,. Autoimmune diseases induced by TNF-targeted terapie. Best Pract Res Clin Rheumatol 2008; 22: 847-61.
38. Al-Niaimi F,. Adalimumab-induced lupus erythematosus. Eur J Dermatol 2009; 19: 380.
39. Statkute L, Ruderman EM,. Novel TNF antagonists for the treatment of rheumatoid arthritis. Expert Opin Investig Drugs 2010; 19: 105-15.
40. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P,; ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 2002; 359: 1541-9.
41. Allanore Y, Sellam J, Batteux F, Job Deslandre C, Weill B, Kahan A,. Induction of autoantibody in refractory rheumatoid arthritis patients treated by infliximab. Clin Exp Rheumatol 2004; 22: 756-8.
42. Ferraro-Peyret C, Coury F, Tebib JG, Bienvenu J, Fabien N,. Infliximab therapy in rheumatoid arthritis and ankylosing apondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. Arthritis Res Ther 2004; 6: R535-43.
43. Caramaschi P, Biasi D, Colombatti M, Pieropan S, Martinelli N, Carletto A, Volpe A, Pacor LM, Mambara LM,. Anti-TNFα therapy in rheumatoid arthritis and autoimmunity. Rheumatol Int 2006; 26: 209-14.
44. Eriksson C, Engstrand S, Sundqvist KG, Rantapaa-Dahlqvist S,. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis 2005; 64: 403-7.
45. Sellam J, Allanore Y, Batteux F, Deslandre CJ, Weill B, Kahan A,. Autoantibody induction in patients with refractory spondyloarthropathy treated with infliximab and etanercept. Joint Bone Spine 2005; 72: 48-52.
46. Klareskog L, Wajdula J, Yeh P, Fatenejad S,. Low autoantibody and anti-etanercept antibody formation and lack of impact on clinical outcomes after five years of treatment with etanercept in patients with rheumatoid arthritis. Arthritis Rheum 2005; 52: S348.
47. De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F,. Infliximab, but not etanercept, induces IgM anti-dsDNA antibodies as main antinuclear reactivity: biological and clinical implications in autoimmune arthritis. Arthritis Rheum 2005; 52: 2192-201.
48. Atzeni F, Sarzi-Puttini P, Dell'Acqua D, De Portu S, Cecchini G, Cruini C, Carrabba M, Meroni PL,. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arthritis Res Ther 2006; 8: R3.
49. Poulalhon N, Begon E, Lebbé C, Lioté F, Lahfa M, Bengoufa D, Morel P, Dubertret L, Bachelez H,. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity. Br J Dermatol 2007; 156: 329-36.
50. Bacquet-Deschryver H, Jouen F, Quillard M, Menard JF, Goeb V, Lequerre T, Mejjad O, Daragon A, Tron F, Le Loet X, Vittecoq O,. Impact of three anti-TNFα biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients. J Clin Immunol 2008; 28: 445-55.
51. Atzeni F, Turiel M, Capsoni F, Doria A, Meroni P, Sarzi-Puttini P,. Autoimmunity and anti-TNF-a agents. Ann N Y Acad Sci 2005; 1051: 559-69.
52. Subramanian S, Yajnik V, Sands BE, Cullen G, Korzenik JR,. Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent. Inflamm Bowel Dis 2011; 17: 99-104.
53. Williams VL, Cohen PR,. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists. Int J Dermatol 2011; 50: 619-25.
54. Ramos-Casals M, Brito-Zeron P, Munoz S, Soria N, Galiana D, Bertolaccini L, Cuadrado MJ, Khamashta MA,. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007; 86: 242-51.
55. Stokes MB, Foster K, Markowitz GS, Ebrahimi F, Hines W, Kaufmen D,. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant 2005; 20: 1400-6.
56. Chadha T, Hernandez JE,. Infliximab-related lupus and associated valvulitis: a case report and review of the literature. Arthritis Rheum 2006; 55: 163-6.
57. Pink AE, Fonia A, Allen MH, Smith CH, Barker JNWN,. Antinuclear antibodies associate with loss of response to antitumour necrosis factor-a therapy in psoriasis: a retrospective, observational study. Br J Dermatol 2010; 162: 780-5.
58. Golberg O, Osborne JE, Hutchinson PE,. Antinuclear antibodies associate with loss of response to antitumour necrosis factor-a therapy in psoriasis but do not necessarily predict treatment failure. Br J Dermatol 2011; 164: 459-60.
59. Iwata D, Namba K, Mizuuchi K, Kitaichi N, Kase S, Takemoto Y, Ohno S, Ishida S,. Correlation between elevation of serum antinuclear antibody titer and decreased therapeutic efficacy in the treatment of Behçet's disease with infliximab. Graefes Arch Clin Exp Ophthalmol 2012; 250 (7): 1081-7.